Cargando…

Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma

BACKGROUND: Lung cancer is responsible of 12.4% and 17.6% of all newly diagnosed cancer cases and mortality due to cancer, respectively, and 5-year survival rate despite all improved treatment options is 15%. This survival rate reaches 66% in the Stage 1 and surgically treated patients. Early diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Ağababaoğlu, İsmail, Önen, Ahmet, Demir, Ayşe Banu, Aktaş, Safiye, Altun, Zekiye, Ersöz, Hasan, Şanlı, Aydın, Özdemir, Nezih, Akkoçlu, Atila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312986/
https://www.ncbi.nlm.nih.gov/pubmed/28178129
http://dx.doi.org/10.1097/MD.0000000000005903
_version_ 1782508289780613120
author Ağababaoğlu, İsmail
Önen, Ahmet
Demir, Ayşe Banu
Aktaş, Safiye
Altun, Zekiye
Ersöz, Hasan
Şanlı, Aydın
Özdemir, Nezih
Akkoçlu, Atila
author_facet Ağababaoğlu, İsmail
Önen, Ahmet
Demir, Ayşe Banu
Aktaş, Safiye
Altun, Zekiye
Ersöz, Hasan
Şanlı, Aydın
Özdemir, Nezih
Akkoçlu, Atila
author_sort Ağababaoğlu, İsmail
collection PubMed
description BACKGROUND: Lung cancer is responsible of 12.4% and 17.6% of all newly diagnosed cancer cases and mortality due to cancer, respectively, and 5-year survival rate despite all improved treatment options is 15%. This survival rate reaches 66% in the Stage 1 and surgically treated patients. Early diagnosis which could not be definitely and commonly achieved yet is extremely critical in obtaining high survival rate in this disease. For this reason; proteomic differences were evaluated using matrix assisted laser desorption ionization (MALDI) mass spectrometry in the subgroups of lung adenocarcinoma and squamous cell carcinoma. METHODS: Fresh tissue samples of 36 malignant cases involving 83.3% (n = 30) men and 16.7% (n = 6) women patients were distributed into 2 groups as early and end stage lung cancer and each group were composed of subgroups including 18 squamous cell carcinoma (9 early stage cases, 9 end stage cases) and 18 adenocarcinoma cases (9 early stage cases, 9 end stage cases). The fresh tissues obtained from the tumoral and matched normal sites after surgical intervention. The differences in protein expression levels were determined by comparing proteomic changes in each patient. RESULTS: In the subgroups of advanced stage adenocarcinoma; tumoral tissue revealed differences in expression of 2 proteins compared with normal parenchymal tissue. Of those; difference in protein expression in heat shock protein 60 (HSP60) was found statistically significant (P = 0.0001). Subgroups of early and advanced stage squamos cell carcinoma have differed in certain 20 protein expression of normal tissue and diseased squamos cell carcinoma. Of those, increased protein expression level of only annexin-2 protein was found statistically significant (P = 0.002). No significant difference was detected in early and advanced stage protein expressions of the tumoral tissues in the subgroups of adenocarcinoma and squamous cell carcinoma. CONCLUSIONS: We conclude that with respect to early diagnosis of lung cancer that HSP60 and annexin-2 proteins are the important biomarkers in the subgroups of adenocarcinoma and squamous cell carcinoma. We also consider that these 2 proteins are molecules which may provide critical contribution in evaluation of prognosis, metastatic potential, response to treatment, and in establishment of differential diagnosis between adenocarcinoma and squamous cell carcinoma.
format Online
Article
Text
id pubmed-5312986
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-53129862017-02-21 Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma Ağababaoğlu, İsmail Önen, Ahmet Demir, Ayşe Banu Aktaş, Safiye Altun, Zekiye Ersöz, Hasan Şanlı, Aydın Özdemir, Nezih Akkoçlu, Atila Medicine (Baltimore) 5700 BACKGROUND: Lung cancer is responsible of 12.4% and 17.6% of all newly diagnosed cancer cases and mortality due to cancer, respectively, and 5-year survival rate despite all improved treatment options is 15%. This survival rate reaches 66% in the Stage 1 and surgically treated patients. Early diagnosis which could not be definitely and commonly achieved yet is extremely critical in obtaining high survival rate in this disease. For this reason; proteomic differences were evaluated using matrix assisted laser desorption ionization (MALDI) mass spectrometry in the subgroups of lung adenocarcinoma and squamous cell carcinoma. METHODS: Fresh tissue samples of 36 malignant cases involving 83.3% (n = 30) men and 16.7% (n = 6) women patients were distributed into 2 groups as early and end stage lung cancer and each group were composed of subgroups including 18 squamous cell carcinoma (9 early stage cases, 9 end stage cases) and 18 adenocarcinoma cases (9 early stage cases, 9 end stage cases). The fresh tissues obtained from the tumoral and matched normal sites after surgical intervention. The differences in protein expression levels were determined by comparing proteomic changes in each patient. RESULTS: In the subgroups of advanced stage adenocarcinoma; tumoral tissue revealed differences in expression of 2 proteins compared with normal parenchymal tissue. Of those; difference in protein expression in heat shock protein 60 (HSP60) was found statistically significant (P = 0.0001). Subgroups of early and advanced stage squamos cell carcinoma have differed in certain 20 protein expression of normal tissue and diseased squamos cell carcinoma. Of those, increased protein expression level of only annexin-2 protein was found statistically significant (P = 0.002). No significant difference was detected in early and advanced stage protein expressions of the tumoral tissues in the subgroups of adenocarcinoma and squamous cell carcinoma. CONCLUSIONS: We conclude that with respect to early diagnosis of lung cancer that HSP60 and annexin-2 proteins are the important biomarkers in the subgroups of adenocarcinoma and squamous cell carcinoma. We also consider that these 2 proteins are molecules which may provide critical contribution in evaluation of prognosis, metastatic potential, response to treatment, and in establishment of differential diagnosis between adenocarcinoma and squamous cell carcinoma. Wolters Kluwer Health 2017-02-10 /pmc/articles/PMC5312986/ /pubmed/28178129 http://dx.doi.org/10.1097/MD.0000000000005903 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 5700
Ağababaoğlu, İsmail
Önen, Ahmet
Demir, Ayşe Banu
Aktaş, Safiye
Altun, Zekiye
Ersöz, Hasan
Şanlı, Aydın
Özdemir, Nezih
Akkoçlu, Atila
Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma
title Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma
title_full Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma
title_fullStr Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma
title_full_unstemmed Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma
title_short Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma
title_sort chaperonin (hsp60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312986/
https://www.ncbi.nlm.nih.gov/pubmed/28178129
http://dx.doi.org/10.1097/MD.0000000000005903
work_keys_str_mv AT agababaogluismail chaperoninhsp60andannexin2arecandidatebiomarkersfornonsmallcelllungcarcinoma
AT onenahmet chaperoninhsp60andannexin2arecandidatebiomarkersfornonsmallcelllungcarcinoma
AT demiraysebanu chaperoninhsp60andannexin2arecandidatebiomarkersfornonsmallcelllungcarcinoma
AT aktassafiye chaperoninhsp60andannexin2arecandidatebiomarkersfornonsmallcelllungcarcinoma
AT altunzekiye chaperoninhsp60andannexin2arecandidatebiomarkersfornonsmallcelllungcarcinoma
AT ersozhasan chaperoninhsp60andannexin2arecandidatebiomarkersfornonsmallcelllungcarcinoma
AT sanlıaydın chaperoninhsp60andannexin2arecandidatebiomarkersfornonsmallcelllungcarcinoma
AT ozdemirnezih chaperoninhsp60andannexin2arecandidatebiomarkersfornonsmallcelllungcarcinoma
AT akkocluatila chaperoninhsp60andannexin2arecandidatebiomarkersfornonsmallcelllungcarcinoma